

Electronic Acknowledgement Receipt

EFS ID:	5096376
Application Number:	10612179
International Application Number:	
Confirmation Number:	5239
Title of Invention:	Method and medicament for inhibiting the expression of a given gene
First Named Inventor/Applicant Name:	Roland Kreutzer
Customer Number:	76634
Filer:	Allyson Russell Hatton
Filer Authorized By:	
Attorney Docket Number:	A2038-706120
Receipt Date:	03-APR-2009
Filing Date:	02-JUL-2003
Time Stamp:	18:58:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	4318
Deposit Account	502762
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	A2038_706120_IDS_ltr.pdf	22012 05176a2f3d425c0342e77eebd380ff559b7 e635	no	1

Warnings:

Information:

2	NPL Documents	Burke_Appearance.pdf	558597 713e2b55c4095b11fb76a5d04e92ab8a8a fe129	no	6
---	---------------	----------------------	---	----	---

Warnings:

Information:

3	NPL Documents	Barlow_Interferon.pdf	621344 e2ef0fafd23d11e3c421e95ae2f3713c61229 d65	no	7
---	---------------	-----------------------	--	----	---

Warnings:

Information:

4	NPL Documents	Decision_EP1144623_translati n_032909.pdf	2370160 6e42775e2baae434ba6ba8f78141c24bb9a b94df	no	50
---	---------------	--	---	----	----

Warnings:

Information:

5	NPL Documents	Decision_revoking_patent_and _grounds_033109.pdf	1293302 cf03108946aa82a5df900659fa01f26d504b c85	no	33
---	---------------	---	--	----	----

Warnings:

Information:

6	NPL Documents	Harada_Absence.pdf	807102 c589fe5dfb80c84c68e8ff04c7eb61b0fe9 f66	no	10
---	---------------	--------------------	--	----	----

Warnings:

Information:

7	NPL Documents	Nakamura_RNase.pdf	1621543 973f4fd8bce2f6792d1d72fa1ad6b9a71bb0 5ff	no	5
---	---------------	--------------------	--	----	---

Warnings:

Information:

8	NPL Documents	Not_Opp_Oppl_062008.pdf	806003 f2358ea377ebc135c1966b0c5ee0a04dce2c 84e6	no	24
---	---------------	-------------------------	--	----	----

Warnings:

Information:					
9	NPL Documents	Not_Opp_Pfizer_061908.pdf	573087 ddd12f908f1e2cd2fc01fc3bd559ff3700a27 4de	no	15
Warnings:					
Information:					
10	NPL Documents	Not_Opp_Sanofi_061608.pdf	1102132 57618d0588cfaa6609a7007daa895f2b4f93 9d7f	no	22
Warnings:					
Information:					
11	NPL Documents	Not_Opp_Silence_062008.pdf	780815 6ec5f14fe60af39dfca6447cb7e35be5cc927 875	no	19
Warnings:					
Information:					
12	NPL Documents	Not_Opp_Sirna_062008.pdf	1769300 23e92860105e4d85e779a2545953970f414 28128	no	38
Warnings:					
Information:					
13	NPL Documents	Submission_Pfizer_DE1008016 7.pdf	183695 aae3efd23845b359084b02fbae92019b702f 4b7c	no	4
Warnings:					
Information:					
14	NPL Documents	Submission_Sirna_DE10080167 _030409.pdf	1868728 caca07d0709ed7efa74a997b0e79210e9c3 09f3d	no	35
Warnings:					
Information:					
15	NPL Documents	Submission_Oppl_DE10080167 _030409.pdf	367768 975779530923437c6e54c0f5eb8371de7be 34b2b	no	7
Warnings:					
Information:					
16	NPL Documents	Patentees_Obser_DE10066235 _Alnylam_020409.pdf	3097966 e4b2a1c77de40657d8928c315c9c6a76f4d 9d989	no	58
Warnings:					
Information:					
17	NPL Documents	Patentees_observ_DE1008016 7_030409.pdf	367768 975779530923437c6e54c0f5eb8371de7be 34b2b	no	7
Warnings:					

Information:					
18	NPL Documents	Submission_Alnylam_trsl_DE1 0080167_030409.pdf	603222 fbdd773b9587ddff1a44b4ef703b00945d2 31dc3	no	21
Warnings:					
Information:					
19	Information Disclosure Statement (IDS) Filed (SB/08)	706121_sb08_040309.pdf	42167 bd8b6bc12da270c7ea54cb29feb756c075b 2dce2	no	5
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
20	Fee Worksheet (PTO-06)	fee-info.pdf	29952 a1ff954ef2930ac3dfcf6425054f59c09d5cea de	no	2
Warnings:					
Information:					
Total Files Size (in bytes):					18886663
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					